SCHEMBL16631251

SCHEMBL16631251

Cc1[nH]c(=O)cc(F)c1[C@@H]1O[C@H](CO)C(O)[C@@H]1F

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDA P32320 1/20 0.37
SYNJ2 O15056 1/20 0.37
SLC28A1 O00337 1/20 0.34
SLC28A2 O43868 1/20 0.34
SLC29A1 Q99808 1/20 0.34
SLC28A3 Q9HAS3 1/20 0.34
TNF P01375 1/20 0.34
IL6 P05231 1/20 0.34
SLC5A2 P31639 6/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
OGA O60502 1/20 0.33
HEXB P07686 1/20 0.33
SLC5A1 P13866 1/20 0.33
KDM4E B2RXH2 1/20 0.33
B4GALT1 P15291 1/20 0.32
P2RY14 Q15391 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631826 0.90 SYNJ2 (0.46) SYNJ2SLC5A2ALDH1A1LMNATSHR
SCHEMBL16631249 0.87 CDA (0.38) CDASYNJ2SLC28A1SLC28A2SLC29A1
SCHEMBL16631817 0.84 TNF (0.36) SYNJ2TNFIL6SLC5A2ALDH1A1
SCHEMBL18079916 0.82 CDA (0.34) CDASYNJ2SLC28A1SLC28A2SLC29A1
SCHEMBL16631175 0.82 CDA (0.35) CDASYNJ2SLC28A1SLC28A2SLC29A1
SCHEMBL16631161 0.79 CDA (0.35) CDASYNJ2TNFIL6ALDH1A1
SCHEMBL18079977 0.78 P2RY2 (0.50) B4GALT1P2RY14
SCHEMBL16631577 0.77 SLC28A1 (0.40) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631823 0.76 SYNJ2 (0.42) SYNJ2SLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631242 0.75 PYGL (0.37) CDASLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 CDA 200/4885SYNJ2 642/4885SLC28A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.